Home › Research › Biomarkers
Blood β-synuclein is related to amyloid PET positivity in memory clinic patients
Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, Ashton NJ, Molfetta GD et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023-04-13
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction β-synuclein is an emerging blood biomarker to study synaptic degeneration in Alzheimer´s disease (AD), but its relation to amyloid-β (Αβ) pathology is unclear. Methods We investigated the association of plasma β-synuclein levels with [18F] flutemetamol positron emission tomography (PET) in patients with AD dementia (n = 51), mild cognitive impairment (MCI-Aβ+ n = 18, MCI- Aβ- n = 30), non-AD dementias (n = 22), and non-demented controls (n = 5). Results Plasma β-synuclein levels were higher in Aβ+ (AD dementia, MCI-Aβ+) than in Aβ- subjects (non-AD dementias, MCI-Aβ-) with good discrimination of Aβ+ from Aβ- subjects and prediction of Aβ status in MCI individuals. A positive correlation between plasma β-synuclein and Aβ PET was observed in multiple cortical regions across all lobes. Discussion Plasma β-synuclein demonstrated discriminative properties for Aβ PET positive and negative subjects. Our data underline that β-synuclein is not a direct marker of Aβ pathology and suggest different longitudinal dynamics of synaptic degeneration versus amyloid deposition across the AD continuum. Highlights Blood and CSF β-synuclein levels are higher in Aβ+ than in Aβ- subjects. Blood β-synuclein level correlates with amyloid PET positivity in multiple regions. Blood β-synuclein predicts Aβ status in MCI individuals.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 51 participants. Blood β-synuclein levels were higher in people with amyloid PET positivity and could predict amyloid status in those with mild cognitive impairment. Its stated limit: The comparison groups were small (as few as 5 healthy controls), and this was a single memory-clinic cohort, so the findings need confirmation in larger, more diverse samples before the test could be used clinically.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Oeckl, P., Bluma, M., Bucci, M., Halbgebauer, S., Chiotis, K., Sandebring-Matton, A., et al. (2023). Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13046
Vancouver
Oeckl P, Bluma M, Bucci M, Halbgebauer S, Chiotis K, Sandebring-Matton A, et al. Blood β-synuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.13046. PMID: 37052206.
BibTeX
@article{oeckl2023-37052206,
author = {Oeckl, P. and Bluma, M. and Bucci, M. and Halbgebauer, S. and Chiotis, K. and Sandebring-Matton, A. and Ashton, N. J. and Molfetta, G. D. and others},
title = {{Blood β-synuclein is related to amyloid PET positivity in memory clinic patients}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2023},
doi = {10.1002/alz.13046},
pmid = {37052206},
url = {https://doi.org/10.1002/alz.13046}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Plasma β-synuclein levels were higher in Aβ+ (AD dementia, MCI-Aβ+) than in Aβ- subjects (non-AD dementias, MCI-Aβ-) with good discrimination of Aβ+ from Aβ- subjects and prediction of Aβ status in MCI individuals.
- Discussion Plasma β-synuclein demonstrated discriminative properties for Aβ PET positive and negative subjects.
- Our data underline that β-synuclein is not a direct marker of Aβ pathology and suggest different longitudinal dynamics of synaptic degeneration versus amyloid deposition across the AD continuum.
Why it matters
Blood β-synuclein levels were higher in people with amyloid PET positivity and could predict amyloid status in those with mild cognitive impairment. The authors state β-synuclein is not a direct marker of amyloid pathology, so it reflects synaptic degeneration rather than the amyloid deposits themselves.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants51
- Evidence strengthModerate
Limitations
The comparison groups were small (as few as 5 healthy controls), and this was a single memory-clinic cohort, so the findings need confirmation in larger, more diverse samples before the test could be used clinically.
How this study scored 59/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 51 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 3.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Markus Otto: h-index 95 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37052206) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.